Noboru Matsumoto

The University of Tokyo, Tokyo, Tokyo-to, Japan

Are you Noboru Matsumoto?

Claim your profile

Publications (2)2.2 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: To introduce our modified procedures of type 1 tympanoplasty and to assess their efficacy. We modified the surgical procedures of type 1 tympanoplasty and have used these procedures since September 1999. The modified points are enlargement of the facial recess approach, no elevation of the posterior meatal skin and the tympanic annulus, and endoaural repair of tympanic membrane perforation. 51 patients with simple chronic otitis media have undergone this modified type 1 tympanoplasty. Postoperative hearing was evaluated according to the criteria proposed by the Otological Society of Japan. The average follow-up period was 15 months (range 6-35). The hearing result was considered successful when the postoperative hearing level satisfied with at least one of three conditions as follows: (1) air-bone gap <15 dB, (2) hearing gain >15 dB, or (3) hearing level >30 dB. The success rate was 94.1%. The average postoperative air-bone gap, hearing gain and hearing level were 3.9, 10.0 and 29.3 dB, respectively. Our modified tympanoplasty is useful to achieve better postoperative hearing results.
    ORL 01/2010; 71 Suppl 1:71-3. · 1.10 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Both reservoir systems for intra-arterial cisplatin and intravenous sodium thiosulfate infusions are low- invasive, safe and effective procedures for treatment of advanced maxillary sinus carcinoma. To use our reservoir system for intra-arterial high-dose cisplatin infusion therapy in patients with advanced maxillary sinus carcinoma. Eight patients with advanced maxillary sinus carcinomas underwent treatment utilizing intra-arterial cisplatin (CDDP) infusion and radiation therapy followed by planned surgical resection. For intra-arterial infusion of high-dose cisplatin, both intra-arterial and intravenous reservoir systems were used. CDDP was infused 4-6 times (mean 5.1) and the total dose of CDDP was between 690 and 910 mg (mean 771 mg). The response rate was 100 with 50% CR and 50% PR and all patients underwent medial maxillectomy. Only 1 T(4) patient had local recurrence and 1 other patient had bilateral neck metastasis.
    ORL 01/2010; 71 Suppl 1:116-22. · 1.10 Impact Factor